Aspen pays £700m for GSK’s blood-clotting drugs

Aspen is to pay £700m for GlaxoSmithKline’s off-patent blood clotting medicines; Arixtra and Fraxiparine including control of its factory in France. GSK will retain control of some markets in Asia for these two products.